Top

Published in:

01-09-2015 | Original Article

Effect of purified eicosapentaenoic acid on red cell distribution width in patients with ischemic heart disease

Authors: Masao Takahashi, Masahiro Myojo, Aya Watanabe, Arihiro Kiyosue, Koichi Kimura, Jiro Ando, Yasunobu Hirata, Issei Komuro

Published in: Heart and Vessels | Issue 5/2015

Abstract

A recent study showed eicosapentaenoic acid (EPA) is a promising treatment for prevention of coronary events in hypercholesterolemic patients. Meanwhile, a high red blood cell distribution width (RDW) is a known risk factor for cardiovascular events. However, few studies have addressed the association between EPA levels and RDW. We examined whether EPA administration reduced the levels of RDW in patients with ischemic heart disease (IHD). We retrospectively analyzed the data of 66 EPA-treated IHD patients, and these EPA-treated patients were compared with control IHD patients. The median follow-up period was 189 days in EPA-treated patients. All patients were not associated with anemia. In the follow-up period, the ratio of EPA levels to arachidonic acid levels (EPA/AA) was significantly increased. A significant decrease was observed in RDW at follow-up [ΔRDW (%); EPA vs. control = −0.34 ± 0.84 (SD) vs. 0.08 ± 0.86, P < 0.01]. These RDW changes were more marked in diabetic patients with high serum levels of high-sensitive C-reactive protein (hs-CRP) [ΔRDW (%); EPA vs. control = −0.53 ± 0.69 vs. 0.56 ± 0.85, P < 0.01]. There was no correlation between the amount of change in EPA/AA and RDW (R = 0.037, P = 0.32), but a significant negative correlation was observed in diabetic patients with high hs-CRP levels (N = 14, R = −0.506, P = 0.046). In conclusion, EPA has the potential to reduce RDW in IHD patients. This effect was intensified especially among diabetic patients with high hs-CRP levels. IHD patients with high RDW levels may be suitable for treatment with purified EPA.

Available only for authorised users

Albert CM, Hennekens CH, O’Donnell CJ (1998) Fish consumption and risk of sudden cardiac death. JAMA 279:23–28CrossRefPubMed

Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, Cobb LA, Copass MK, Psaty BM, Lemaitre R, Retzlaff B, Childs M, Knopp RH (1995) Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 274:1363–1367CrossRefPubMed

Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369:1090–1098CrossRefPubMed

Zhang M, Hagiwara S, Matsumoto M, Gu L, Tanimoto M, Nakamura S, Kaneko S, Gohda T, Qian J, Horikoshi S, Tomino Y (2006) Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress. Metabolism 55:1590–1598CrossRefPubMed

von Schacky C, Weber PC (1985) Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 76:2446–2450CrossRef

Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM (2009) Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med 169:515–523CrossRefPubMedCentralPubMed

Patel KV, Mohanty JG, Kanapuru B, Hesdorffer C, Ershler WB, Rifkind JM (2013) Association of the red cell distribution width with red blood cell deformability. Adv Exp Med Biol 765:211–216CrossRefPubMed

International Expert Committee (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32:1327–1334CrossRef

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219CrossRefPubMed

10.

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult––2009 recommendations. Can J Cardiol 25:567–579CrossRefPubMedCentralPubMed

11.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992CrossRefPubMed

12.

Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, JELIS Investigators (2011) Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 18(2):99–107CrossRefPubMed

13.

Arima H, Kubo M, Yonemoto K, Ninomiya T, Tanizaki Y, Hata J, Matsumura K, Iida M, Kiyohara Y (2008) High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol 28:1385–1391CrossRefPubMed

14.

Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103(13):1813–1818CrossRefPubMed

15.

Kondo T, Ogawa K, Satake T, Kitazawa M, Taki K, Sugiyama S, Ozawa T (1986) Plasma-free eicosapentaenoic acid/arachidonic acid ratio: a possible new coronary risk factor. Clin Cardiol 9:413–416CrossRefPubMed

16.

Ueeda M, Doumei T, Takaya Y, Ohnishi N, Takaishi A, Hirohata S, Miyoshi T, Shinohata R, Usui S, Kusachi S (2011) Association of serum levels of arachidonic acid and eicosapentaenoic acid with prevalence of major adverse cardiac events after acute myocardial infarction. Heart Vessels 26(2):145–152CrossRefPubMed

17.

Hayakawa S, Yoshikawa D, Ishii H, Tanaka M, Kumagai S, Matsumoto M, Hayashi M, Sugiura T, Hayashi K, Ando H, Amano T, Murohara T (2012) Association of plasma omega-3 to omega-6 polyunsaturated fatty acid ratio with complexity of coronary artery lesion. Intern Med 51:1009–1014CrossRefPubMed

18.

Hasegawa T, Otsuka K, Iguchi T, Matsumoto K, Ehara S, Nakata S, Nishimura S, Kataoka T, Shimada K, Yoshiyama M (2013) Serum n-3 to n-6 polyunsaturated fatty acids ratio correlates with coronary plaque vulnerability: an optical coherence tomography study. Heart Vessels. doi:10.1007/s00380-013-0404-4

19.

Grundy SM (2001) Dietary fat: at the heart of the matter. Science 293(5531):801–804CrossRefPubMed

20.

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC (2010) Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212:252–259CrossRefPubMed

21.

Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, Koyama M, Okada N, Nakashima N, Masuya D, Yoshimatsu H, Suzuki Y (2013) Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One 8:e80240CrossRefPubMedCentralPubMed

22.

Dugdale AE (2006) Predicting iron and folate deficiency anaemias from standard blood testing: the mechanism and implications for clinical medicine and public health in developing countries. Theor Biol Med Model 3:34CrossRefPubMedCentralPubMed

23.

James SK, Lindahl B, Timmer JR, Ottervanger JP, Siegbahn A, Stridsberg M, Armstrong P, Califf R, Wallentin L, Simoons ML (2006) Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol 97:167–172CrossRefPubMed

Title: Effect of purified eicosapentaenoic acid on red cell distribution width in patients with ischemic heart disease
Authors: Masao Takahashi
Masahiro Myojo
Aya Watanabe
Arihiro Kiyosue
Koichi Kimura
Jiro Ando
Yasunobu Hirata
Issei Komuro
Publication date: 01-09-2015
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 5/2015
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-014-0526-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Effect of purified eicosapentaenoic acid on red cell distribution width in patients with ischemic heart disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Risk factors for rehospitalization in heart failure with preserved ejection fraction compared with reduced ejection fraction

High incidence and severity of periodontitis in patients with Marfan syndrome in Japan

A high-risk patient with long-QT syndrome with no response to cardioselective beta-blockers

Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients

Efficacy and safety of novel epicardial circumferential left atrial ablation with pulmonary vein isolation in sustained atrial fibrillation

Development of new risk score for pre-test probability of obstructive coronary artery disease based on coronary CT angiography

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page